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Abstract: Triazole-resistance has been reported increasingly in Aspergillus fumigatus. An international
expert team proposed to avoid triazole monotherapy for the initial treatment of invasive aspergillosis
in regions with >10% environmental-resistance, but this prevalence is largely unknown for most
American and African countries. Here, we screened 584 environmental samples (soil) from urban and
rural locations in Mexico, Paraguay, and Peru in Latin America and Benin and Nigeria in Africa for
triazole-resistant A. fumigatus. Samples were screened using triazole-containing agars and confirmed
as triazole-resistant by the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
broth dilution reference method. Isolates were further characterized by cyp51A sequencing and short-
tandem repeat typing. Fungicide presence in samples was likewise determined. Among A. fumigatus
positive samples, triazole-resistance was detected in 6.9% (7/102) of samples in Mexico, 8.3% (3/36)
in Paraguay, 9.8% (6/61) in Peru, 2.2% (1/46) in Nigeria, and none in Benin. Cyp51A gene mutations
were present in most of the triazole-resistant isolates (88%; 15/17). The environmentally-associated
mutations TR34/L98H and TR46/Y121F/T289A were prevalent in Mexico and Peru, and isolates
harboring these mutations were closely related. For the first time, triazole-resistant A. fumigatus was
found in environmental samples in Mexico, Paraguay, Peru, and Nigeria with a prevalence of 7–10%
in the Latin American countries. Our findings emphasize the need to establish triazole-resistance
surveillance programs in these countries.
Keywords: Aspergillus fumigatus; antifungal resistance; epidemiology; environment; America; Africa
1. Introduction
Aspergillus fumigatus is a globally distributed environmental fungus that plays a major
role in the decomposition of organic matter. It can adapt to diverse environments and
produce vast numbers of spores that assure its survival and dissemination. A. fumigatus
is usually not a primary human pathogen, but, due to the rise of conditions that require
immunosuppressive medications, such as cancer or transplantations, it has become an
important agent of opportunistic infections [1]. Recently, A. fumigatus was also described as
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a co-infecting pathogen in patients with severe influenza and COVID-19 [2,3]. Triazole an-
tifungals, such as voriconazole, posaconazole, and isavuconazole, play a crucial role in the
prophylaxis and treatment of aspergillus-related diseases [4,5], but increasing reports of
triazole-resistance in A. fumigatus are a serious concern [6].
Triazole-resistant infections can arise either after prolonged triazole antifungal therapy
in patients (patient route of infection) or after exposure to triazole-resistant conidia in the
environment (environmental route); the latter has been considered as the main route of
infection in patients with invasive aspergillosis [6,7]. It is generally accepted that the
development and selection of triazole-resistant A. fumigatus in the environment occurs sec-
ondary to the exposure of triazole-fungicides (demethylation inhibitors (DMIs)), which are
commonly used for crop protection and preservation of materials [8,9]. Environments that
contain azole fungicides and allow the fungus to complete all of its growth-cycle stages,
such as flower bulbs, green material, and wood chipping waste management sites, are
referred to as “hotspots” and have been described to facilitate the emergence, amplification,
and spread of mutations that confer triazole-resistance in A. fumigatus [9]. The most fre-
quently reported mechanisms conferring triazole-resistance in A. fumigatus are mutations
in the cyp51A gene, a gene involved in the biosynthesis of ergosterol [6,7,10]. Among these,
the environmentally associated TR34/L98H and TR46/Y121F/T289A consisting of a tandem
repeat (TR) in the cyp51A-promoter region and a single or multiple amino acid substitutions
are the most prevalent [6,11].
Infections with triazole-resistant A. fumigatus have been associated with higher proba-
bilities of therapeutic failure and increased mortality in patients [12,13]. An international
expert group has proposed to modify the recommended first-line triazole monotherapy for
the treatment of invasive aspergillosis (IA) if environmental triazole-resistance prevalence
is >10% to either a combination of a triazole with an echinocandin or liposomal ampho-
tericin B (L-AmB) prior to the availability of susceptibility test results or in the absence of a
positive culture [5,14,15].
Although various studies have investigated epidemiological data on triazole-resistance
in A. fumigatus, the vast majority of countries in the world lack this information as triazole-
resistance screening is not routinely performed in these regions [6]. To gain more insight
into the current situation of triazole resistance in A. fumigatus, we conducted environmental
epidemiological studies in countries that lack this information, i.e., Mexico, Peru, and
Paraguay in America, and with Benin and Nigeria in Africa.
2. Materials and Methods
2.1. Environmental Sample Collection
We established collaborations with researchers with a known interest in mycology
to collect and screen environmental samples for triazole-resistant A. fumigatus. All part-
ners received a detailed protocol for the collection, storage, and shipment of samples in
addition to necessary materials. Each collaborator was requested to collect at least 100
environmental samples consisting of 5 g of soil from pre-defined locations in urban and
rural areas, such as parks, city and hospital flowerbeds, agricultural fields, greenhouses,
gardens, compost, and commercial soil, as stated in our protocol. Environmental samples
were collected using a disposable sterile spoon from the surface up to two cm depth where
most organic matter is located. Once collected, samples were shipped to our institution
for further analysis. Import license for environmental samples was granted by the Federal
Agency for Safety of the Food Chain (FASFC) and the Flemish Minister for Environment,
Nature and Agriculture, according to the European Union regulations Commission Del-
egated Regulations 2015/2446, 952/2013 and article 34 of the Royal Decree nr. 7 of 29
December 1992.
2.2. Triazole Antifungals Resistance Screening
Two grams from each environmental sample were initially dissolved in 8 mL contain-
ing 0.85% Sodium Chloride (NaCl) and 0.1% Tween-20 for analysis. From this, 100 µL was
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inoculated to each of the following Sabouraud dextrose agar plates containing: no antifun-
gal (control; growth of any fungi), 4 mg/L itraconazole (false positives were previously
observed when using 2 mg/L in our pilot study) and 2 mg/L of voriconazole (both from
Sigma-Aldrich, St. Louis, MO, USA). As A. fumigatus has the ability to grow at high tem-
peratures, agar plates were incubated at 48 ◦C to restrict the growth of most environmental
fungi [16]. Agar plates were monitored for growth for 72 h, which is a short triazole-
exposure length with no de novo triazole-resistance induction reports [17]. When growth
of A. fumigatus complex isolates (based on macro/microscopic characteristics), one isolate
from the control and up to 5 from the triazole-containing agar plates were sub-cultured
for further investigation. Selected isolates were categorized as A. fumigatus sensu-strictu
via MALDI-TOF mass spectrometry (Bruker Daltonics, Bremen, Germany) and the Mass
Spectrometry Identification platform (MSI) reference spectra database [18]. In case of
inconclusive identification, sequencing of the beta tubulin gene was performed as described
before [10].
2.3. Triazole-Resistance Phenotype Determination and Cyp51A Gene Sequencing
Minimal inhibitory concentrations (MIC) of itraconazole, voriconazole, posaconazole,
and amphotericin B (all from Sigma-Aldrich, St. Louis, MO, USA) of suspected resis-
tant isolates were determined using the EUCAST (European Committee on Antimicrobial
Susceptibility Testing) broth microdilution reference method for filamentous fungi [19].
Triazole-resistant phenotype was confirmed if at least one MIC value was above the
established EUCAST resistance clinical breakpoints (voriconazole >1, itraconazole >1,
posaconazole >0.25, mg/L) [20]. Only one confirmed triazole-resistant isolate was se-
lected for further analysis from samples harboring multiple resistant isolates with similar
phenotypes (± 1 MIC variation) as they were considered the same. MICs from all triazole-
resistant and 22 randomly selected susceptible A. fumigatus isolates to the azole-fungicide
tebuconazole (Sigma-Aldrich, St. Louis, MO, USA) were likewise determined using the
EUCAST methodology. Isolates with MIC ≥ 4 mg/L were considered resistant to tebu-
conazole [21]. Sequencing of the cyp51A gene and its promoter region was performed in
confirmed triazole-resistant isolates as previously described [22].
2.4. Genotyping Samples
Genetic relatedness between isolates was determined using two separate multiplex
PCRs specific for A. fumigatus (M3, M4), each amplifying three short tandem repeats
(STRs) of three trinucleotide loci (M3; STRAf3-A, B, C primers) and three tetranucleotide
loci (M4; STRAf4-A, B, C primers) as indicated earlier [23,24]. Briefly, 4 µL of cleaned
PCR product was combined with 20 µL mix of HiDi Formamide and GeneScan 500 LIZ
size standard (Applied Biosystems, Foster City, CA, USA) for fragment detection on a
96-capillary array ABI3730xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Assignment of STR numbers for each marker was performed using the Peak Scanner
Software v1.0 (Applied Biosystems, Foster City, CA, USA). Genetic distance similarity
(Euclidean method) and hierarchical relationship (Ward’s minimum variance linkage
method; ggplot2 package) based on STRs between our selected isolates and openly available
worldwide selected isolates (clinical and environmental) contained within the AfumID-
STR profile application were performed using the statistical computing and graphics
software R (v4.0.3) [11,25]. Worldwide isolates included at least one susceptible and one
triazole-resistant A. fumigatus isolate per continent (24 triazole-resistant and 22 wild-types).
Based on reported worldwide populations of the AfumID platform, our triazole-resistant
isolates were lastly associated with either their described resistant (clade A) or susceptible
(clade B) populations (principal component analysis) [11].
2.5. Fungicide Concentrations in Environmental Samples
The presence or absence of triazole fungicides in environmental samples (2 g per
sample) was determined using multi-residue liquid chromatography-mass spectrometry
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(Primoris, Zwijnaarde, Belgium). This methodology detects and quantifies >500 pes-
ticides in soil, including triazole fungicides, with a residue limit of detection between
0.01–0.05 mg/kg. All environmental samples from which triazole-resistant A. fumigatus was
isolated were individually analyzed. Environmental samples where no triazole-resistant A.
fumigatus was found were combined per country for analysis.
3. Results
3.1. Triazole-Resistance in A. fumigatus Analysis
We screened 584 environmental samples in total for triazole-resistance in A. fumigatus.
Overall environmental screening results from all analyzed countries are depicted in Table 1.
Detailed analysis per country is as follows:
3.1.1. Mexico
In total, 198 environmental samples (Table 1) were analyzed from 2 regions; 98 sam-
ples from Mexico City (urban setting) and 100 samples from Celaya, Guanajuato (urban
and rural settings). Growth of any fungi and of A. fumigatus complex was observed in
172 samples (87%) and 102 samples (51.5%), respectively. Triazole-resistant A. fumigatus
sensu-stricto isolates were found in 7 samples, resulting in a resistance prevalence of 6.9%
among A. fumigatus positive samples. The screened regions in Mexico City and Guanajuato,
in addition to the locations of triazole-resistant positive samples are depicted in Figure S1.
All resistant isolates were collected in urban sites (7/7), five in Guanajuato (71%) and two in
Mexico City (29%). The mycological characteristics of triazole-resistant isolates are depicted
in Table 2. Resistance to all tested triazole antifungals was observed in 6 of the 7 isolates
(86%), while none were resistant to amphotericin B. Cyp51A gene sequencing analysis
reported the TR34/L98H (5/7, 71.4%) or the TR46/Y121F/T289A (1/7, 14.3%) mutations
in most isolates, and one isolate (1/7, 14.3%) without mutations. All isolates harboring
environmentally associated tandem repeat mutations (6/6) showed cross-resistance to
tebuconazole (MIC ≥4 mg/L) with MICs ranging between 8–32 mg/L. No cross-resistance
to tebuconazole was observed in the triazole-resistant isolate with wild-type cyp51A. Tri-
azole fungicides were not detected in any tested soil samples containing susceptible or
resistant isolates.
3.1.2. Paraguay
We screened 85 samples from which growth of any fungi was observed in 62 (73%)
and of A. fumigatus species complex in 36 samples (42.4%), respectively (Table 1). From this,
triazole-resistance was confirmed in three A. fumigatus sensu-stricto isolates with a preva-
lence of 8.3% among A. fumigatus complex positive samples. Two isolates harbored amino
acid substitutions in the cyp51A gene (F46Y, M172V, E427K and F46Y, M172V, N248T,
D255E, E427K), and one did not (Table 2). Resistant isolates presented MICs just above the
EUCAST resistance clinical breakpoints of >1 mg/L for voriconazole (range of 2–4 mg/L)
and were susceptible to posaconazole, itraconazole, and amphotericin B. MICs of tebu-
conazole ranged between 2–4 mg/L (resistant ≥ 4 mg/L). All samples originated from
urban locations. The screened region (Asuncion metropolitan area) and the locations of
triazole-resistant positive samples are reported in Figure S2. Triazole fungicides were not
detected in any of the analyzed soil samples.
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Table 1. Environmental screening of triazole resistant Aspergillus fumigatus (A. fumigatus) per country.
Country Samples (No.) % of TotalSamples





Growth any fungi 172 87.0
A. fumigatus species 102 51.5
Triazole-resistant A. fumigatus 7 3.5 6.9
Cyp51A gene mutation 6 3.0 5.9
No mutation cyp51A gene mutation 1 0.5 1.0
Paraguay
Total samples 85
Growth any fungi 62 73
A. fumigatus species 36 42.4
Triazole-resistant A. fumigatus 3 3.5 8.3
Cyp51A gene mutation 2 2.4 5.6
No mutation cyp51A gene mutation 1 1.2 2.8
Peru
Total samples 106
Growth any fungi 87 82.1
A. fumigatus species 61 57.5
Triazole-resistant A. fumigatus 6 5.7 9.8
Cyp51A gene mutation 6 5.7 9.8
No mutation cyp51A gene mutation 0 0.0 0.0
Benin
Total samples 95
Growth any fungi 86 90.5
A. fumigatus species 25 26.3
Triazole-resistant A. fumigatus 0 0.0 0.0
Cyp51A gene mutation 0 0.0 0.0
No mutation cyp51A gene mutation 0 0.0 0.0
Nigeria
Total samples 100
Growth any fungi 93 93
A. fumigatus species 46 46
Triazole-resistant A. fumigatus 1 1.0 2.2
Cyp51A gene mutation 1 1.0 2.2
No mutation cyp51A gene mutation 0 0.0 0.0
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Table 2. Mycological characteristics of triazole-resistant Aspergillus fumigatus environmental isolates.
Country—Regions: Sample ID Number
EUCAST MIC (mg/L) 1
cyp51A Gene Mutation Location 3AMB VCZ POS ITC TEB 2
Mexico
Guanajuato 47 1 4 0.5 >8 8 TR34/L98H Flower bed (U)
Guanajuato 48 1 4 0.5 16 0.5 No mutation Park (U)
Guanajuato 49 0.5 2 1 >16 8 TR34/L98H Commercial compost (U)
Guanajuato 50 1 4 0.5 >16 8 TR34/L98H/S297T/F495I Commercial compost (U)
Guanajuato 51 1 16 2 >16 32 TR34/L98H Flower bed (U)
Mexico City 52 0.5 4 0.5 >16 16 TR34/L98H Greenhouse (U)
Mexico City 53 0.5 >16 0.5 1 16 TR46/Y121F/T289A Flower bed (U)
Paraguay
Asunción 95 0.5 2 0.25 1 4 F46Y, M172V, E427K Flower bed (U)
Asunción 96 1 4 0.25 1 2 No mutation Flower bed (U)
Asunción 97 1 2 0.25 1 4 F46Y, M172V, N248T, D255E,E427K Flower bed (U)
Peru
Lima City 66 1 2 1 >16 8 TR34/L98H/S297T/F495I Agricultural field (R)
Lima City 67 1 8 1 >16 16 TR34/L98H Agricultural field (R)
Lima City 68 0.25 8 1 >16 16 TR34/L98H Park (U)
Lima City 69 0.5 8 1 >16 16 TR34/L98H Flower bed (U)
Lima City 70 0.5 4 0.5 >16 32 TR34/L98H Agricultural field (R)
Lima City 71 0.5 8 1 >16 64 TR34/L98H Commercial compost (U)
Nigeria
Lagos Ibadan 90 1 2 0.25 4 4 M172V Flower bed (U)
1 Minimal inhibitory concentration (MIC) determined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference method for filamentous fungi. Triazole-resistant
phenotype was confirmed if at least one MIC value was above the EUCAST resistance clinical breakpoint (voriconazole > 1, itraconazole >1, posaconazole >0.25, mg/L). 2 Triazole fungicide tebuconazole;
Resistance ≥4 mg/L. 3 Location: Urban area (U), rural area (R). Abbreviations: ID = identification, AMB = amphotericin B, VCZ = voriconazole, POS = posaconazole, ITC = itraconazole, TEB = tebuconazole.
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3.1.3. Peru
In Peru, 106 samples were investigated for triazole-resistance (Table 1). Growth of any
fungi was detected in 87 samples (82.1%) from which 61 contained A. fumigatus species
complex isolates (57.5%). We identified six samples with triazole-resistant isolates, resulting
in a prevalence among A. fumigatus positive samples of 9.8% (6/61). Resistance to all
triazole antifungals tested was observed in all isolates (Table 2). Likewise, cross-resistance
to the azole-fungicide tebuconazole was detected in all isolates. Resistance to amphotericin
B was not found. All six triazole-resistant isolates presented the TR34/L98H cyp51A gene
mutations (100%), with one isolate containing two additional amino acid substitutions
(TR34/L98H/S297T/F495I). Sampling locations were evenly distributed between rural (3/6,
50%) and urban regions (3/6, 50%) (Figure S3). The presence of two triazole-fungicides,
propiconazole and tebuconazole, was confirmed in samples from Peru. Propiconazole was
detected in one out of the six triazole-resistant samples (Sample ID 69, 0.012 mg/kg) and
tebuconazole in the combined susceptible sample analysis (0.031 mg/kg).
3.1.4. Benin
Samples from 95 locations from Benin were screened for triazole-resistance in A.
fumigatus (Table 1). In total, 86 samples showed growth of any fungi (90.5%), of which
25 samples contained A. fumigatus complex isolates (26.3%). In our analysis, we did not
find any triazole-resistant isolates or the presence of triazole fungicides amongst tested
samples. Screened regions are reported in Figure S4.
3.1.5. Nigeria
One hundred samples were screened and analyzed in Nigeria (Table 1). The presence
of any fungi and A. fumigatus species complex was found in 93 (93.0%) and 46 (46.0%)
samples. Only one sample was confirmed to contain a triazole-resistant isolate (urban
origin), providing a prevalence of 2.2% (1/46) among culture-positive A. fumigatus samples.
Mycological characteristics of this isolate are depicted in Table 2. Low levels of resistance
were observed in this isolate for all triazole antifungals tested. Similarly, the tebuconazole
MIC of 4 mg/L was at the lower limit of the established resistance level (≥4 mg/L).
Sequencing of the cyp51A gene revealed the amino acid change M172V. The location of
the screened regions can be found in Figure S5. No triazole fungicides were present in the
resistant or combined susceptible samples.
3.2. Genetic Relatedness Analysis
Genetic relationship based on microsatellite profile (STR) between selected A. fumigatus
isolates from our study (all triazole-resistant) and worldwide isolates from the freely
available AfumID-application metadata is depicted in Figure 1.
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Based on our phylogenetic analysis, isolates could be situated into two clades, clade
I (red-sample ID number) and clade II (black-sample ID number). Within clade I, we
observed a close genetic relationship among most triazole-resistant isolates from Mexico
(85%, 6/7) an Peru (100%, 6/6). Triazole-resistant isolates from Nigeria and Paraguay were
located in clade II with no strong close genetic relati nship between isolates. More riazole-
resistant isolates from our study belonged to clad I (12/17, 70%) compared to clade II
(5/17, 30%). Based on the interactive web-based tool AfumID metadata, all of our triazole-
resistant isolates harboring TR34/L98H or TR46/Y121F/T289A cyp51A gene mutations
(12/17) could be associated with their worldwide triazole-resistant population group
(Clade A); triazole-resistant isolates harboring other or no cyp51A gene mutations (5/17)
were associated to clade B were most isolates from the non-resistant population locate
(Figure S6). No identical genotype was found between our isolates. Detailed characteristics
of genotyped isolates can be found in Figure S7.
4. Discussion
Hereby, we report for the first time the recovery of triazole-resistant A. fumigatus iso-
lates from environmental samples in three American countries Mexico, Peru and Paraguay,
and in the African country of Nigeria with a triazole-resistance prevalence of 6.9% (7/102),
8.3% (3/36), 9.8% (6/61), and 2.2% (1/46), respectively, among A. fumigatus culture-positive
samples. No triazole-resistant isolates were detected in samples from Benin.
Epidemiological data on resistance to triazole antifungals in A. fumigatus is limited for
the American and African continents. In North America, an environmental study from the
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south-eastern region of the United States (USA) reported the presence of triazole-resistant
A. fumigatus in 19% (38/200) of analyzed isolates from 8 out of 35 locations (22%) [26].
Two passive surveillance studies performed on clinical isolates reported contrasting triazole-
resistant prevalences of 12% (26/220) and 1.4% (20/1356), respectively [27,28]. A lower
triazole-resistance prevalence of 0.1% (1/807 patients) was stated in a Canadian surveillance
study [29]. In Mexico, the remaining country in the North American region, we found
an overall triazole-resistance prevalence of 6.9%. When divided per screened region,
we observed in Guanajuato, a region with intense agricultural activities, a higher prevalence
of 11.6% (5/43) compared to 3.7% (2/55) in Mexico City. Interestingly, all triazole-resistant
samples in both regions originated from urban locations and no fungicide could be detected
in our samples. The use of fungicides in Mexico, including azole-fungicides, is high
(55% of all used pesticides in Mexico), representing 4% of global consumption with an
average-use of 28,601 tons per year (1.45 kg/used-hectare) [30,31]. Amongst authorized
agricultural fungicides, four groups that compromise the production of ergosterol by
inhibition of the cyp51A enzyme (sterol biosynthesis inhibitors (SBI)) have been described:
demethylation inhibitors (DMIs; SBI class I), amines (SBI class II), keto-reductase inhibitors
(SBI class III) and squalene monooxygenases (SBI class IV) [32]. Based on a homology
cyp51A protein model of A. fumigatus, it was reported that most compounds from the
DMIs group adopt similar positions upon docking in the protein’s active site as those
observed for medical triazoles [33]. The core structure of the DMIs propiconazole and
bromuconazole (long-tailed fungicides) were most similar to itraconazole and posaconazole
(long-tailed antifungals), while tebuconazole and epoxiconazole (short-tailed fungicides)
relate more to voriconazole (short-tailed antifungal) [33,34]. The structure of the DMIs
difenoconazole was different as it docked into the access channel of medical azoles, a region
associated with conferring triazole-resistance. These five fungicides showed complete loss
of in vitro activity against resistant isolates and their use might play an important role in
environmental cross-resistance selection to medical triazoles.
In Mexico, tebuconazole is the most sold fungicide, followed by difenoconazole, prop-
iconazole and epoxiconazole, with an average-use between 0.1–0.3 kg/used-hectare [35,36].
However, we could not detect the presence of any DMIs in any of our samples from Mexico.
Nonetheless, the majority of triazole-resistant isolates (6/7) showed cross-resistance to
tebuconazole. These isolates were most likely selected in the environment in locations
where DMIs are present, which may be more prevalent in Guanajuato and spread through
these regions. Our reported overall triazole-resistance prevalence of 6.9% is similar to
the 8.3% described in a tertiary care facility located in Mexico City (2/24) [37], but higher
than the one observed in our screened regions in Mexico City (3.7%), which included the
location of this facility. However, tertiary care facilities in Mexico generally treat patients
from different regions. However, as the number of samples from their study was small,
we cannot infer any conclusions.
In the South American region, our reported triazole-resistance prevalence in Paraguay
(8.3%) and in Peru (9.8%) is higher to one reported from Brazil (4.5%, 2/44 cases) but much
lower than the ones reported from two environmental studies from Colombia of 47.1% (8/17)
and 44.1% (15/34), respectively [38–40]. However, due to the low sample numbers in these
studies, it is unclear how representative these prevalence data are. The triazole-resistant
isolates from Colombia were mainly found in flower fields and vegetable crop zones; there-
fore, their reported prevalence might be more representative of hotspots with an increased
selection of resistant isolates and not for the global situation in this country. According to the
latest reports of the Food and Agriculture Organization of the United Nations (FAO) [31],
Colombia has the highest fungicides-use per country in that region with an average-use of
7214 tons (13.5 kg/used-hectares) compared to the used in Paraguay (4556 tons; 3.82 kg/used-
hectare) and Peru (1189 tons; 1.0 kg/used-hectare). In Peru, currently only tebuconazole and
propiconazole have national use registration [41,42]. From these, tebuconazole is the most
used with and average-use of 0.10–0.16 kg/used-hectare [35,41]. In Paraguay, several DMIs
are authorized for agricultural use [43], yet tebuconazole and propiconazole are the most
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frequent with a 0.10 and 0.12 kg/used-hectare average-use, respectively [35,44]. The presence
of higher concentrations (0.15–0.69 mg/kg) and/or combination of detected azole-fungicides
(four) in the Colombian samples compared to our detected concentrations in Peru (propi-
conazole 0.012, tebuconazole 0.031 mg/kg) and none in Paraguay might play a role in the
selection and the observed differences in prevalence. A recent prospective study from Peru,
reported a triazole-resistance prevalence of 2.1% among clinical isolates (3/143), which is
lower than our reported prevalence of 9.8% [45]. Half of the isolates included in their study
were cultured from patients with a history of pulmonary tuberculosis with suspected chronic
pulmonary aspergillosis. Colony testing of up to five colonies is recommended to increase
sensitivity for triazole-resistance detection [5]. Within this study, only one A. fumigatus
colony was analyzed from each sample, increasing the risk of selecting a susceptible isolate
in patients co-infected with triazole-resistant isolates [46], which could contribute to the
observed differences in prevalence.
Among our two screened countries in Western Africa, we found only one triazole-
resistant isolate in Nigeria, resulting in a low prevalence of 2.2% (1/46) and none in Benin
(0/25) amongst A fumigatus positive samples. Triazole-resistance in A. fumigatus in Africa
has been reported in Burkina Faso in Western Africa and in Tanzania and Kenya in Eastern
Africa, countries characterized by extensive farming, greenhouses, and/or horticultural
practices. As reported in Nigeria, the study from Burkina Faso likewise described a low
environmental triazole-resistance prevalence of 2.0% (1/51) amongst A. fumigatus positive
samples [47]. In contrast, an environmental study performed in urban and rural locations
in the Eastern African country of Tanzania reported triazole-resistant A. fumigatus in 37.0%
(10/27) of their A. fumigatus positive samples [48]. In Kenya, a study conducted in soil
samples from agricultural sites reported 27.1% (13/48) to harbor resistant A. fumigatus
isolates to at least one triazole-antifungal [49].
Within our analyzed samples, we did not detect the presence of any fungicides.
DMIs fungicides are authorized in all the stated African countries. However, information
concerning the average-use of triazole-fungicides in these countries could not be found,
yet the use of pesticides, including fungicides, have been reported in Kenya, Tanzania, and
Nigeria, with a use per area of cropland of 0.43, 0.1, and 0.1 kg/used-hectare; in Benin and
Burkina Faso, studies refer to the use of pesticides, but no data concerning used amounts
per area could be found [31,50–52]. The use of pesticides seems comparable between these
countries. However, the known extensive use of fungicides in the flower and horticultural
industry in Kenya and in the farming regions of Tanzania likely established environments
(hot spots) that enabled the selection and dissemination of triazole-resistant isolates in the
immediacies of the screened locations in these countries that could explain the increased
prevalences observed [49,53]. Whether our observed low prevalence of triazole-resistant A.
fumigatus isolates of 2.2% in Nigeria or its absence in Benin represents current situations or
is secondary to sampling locations will require further investigation.
With regard to cyp51A gene mutations, the most commonly reported environmentally
associated TR34/L98H mutations were the most prevalent resistance mechanism in our
triazole-resistant isolates from Peru (100%, 6/6) and Mexico (71%, 5/7), with two isolates
harboring two additional substitutions (S297T, F495I). Similarly, this is the only mutation
reported in clinical isolates from Peru (one isolate) and Mexico (two isolates), supporting
the link between environment-patient transmission in these countries. Isolates harboring
this mutation have also been reported in the USA, Brazil, and Colombia [26–28,38–40].
Interestingly, three samples harboring TR34/L98H triazole-resistant isolates from Mexico
(two samples) and Peru (one sample) were retrieved from locally produced commer-
cially available compost. The prevalence of triazole-resistant A. fumigatus in commercial
compost was the highest amongst all screened locations in Mexico (15%; 2/13 compost-
samples) but not in Peru (5%, 1/19 compost-samples), where agricultural locations were
(14.3%, 3/21 agricultural-samples). We could not detect the presence of fungicides in any
of these three samples that could explain our finding, yet this niche may pose a potential
risk for triazole-resistance dissemination and requires further investigation. We found one
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isolate harboring the TR46/Y121F/T289A mutation in Mexico, the second most commonly
reported environmentally-associated mutation. This mutation has also been reported in Ar-
gentina, Colombia, and the USA [38–40,54]. Most of our isolates harboring the TR34/L98H
and TR46/Y121F/T289A mutations showed a close genetic relationship (clade I; 92%,11/12)
and could be likewise associated to the triazole-resistant population clade (A-Blue) within
the AfumID-application metadata (worldwide isolates), suggestive of a probable shared
common ancestor among these isolates and a global distribution [11].
The remaining cyp51A mutations were the M172V in one isolate from Nigeria and a
combination of the F46Y, M172V, N248T, D255E, and E427K in two isolates from Paraguay.
In the two isolates from Paraguay, only the MIC value for voriconazole was elevated
(2 mg/L) and fell into the area of technical uncertainty (ATU). These amino acid substi-
tutions are located in the periphery of the protein and not in regions conferring azole-
resistance and have been reported, as well in susceptible isolates, inferring these variances
as cyp51A gene polymorphisms [7,10,24,55–58]. Regardless, our genetic relatedness analy-
sis located isolates harboring these mutations in clade II where broad genetic diversities
and most susceptible isolates were found (87.5%, 49/56), implying that these isolates
were most likely selected independently in the environment and did not originate from a
common ancestor.
The finding of triazole-resistant A. fumigatus spores in the environments of Mexico,
Nigeria, Paraguay and Peru represents a public health concern in these countries. It is
recommended that in regions with known triazole-resistance, all clinically relevant isolates
should be subjected to susceptibility testing, but this is not the case in most centers in
these countries [5]. Agar-based screening methods for triazole-resistance can be helpful to
select colonies for susceptibility testing [59], reducing cost and hands-on time compared to
carrying out susceptibility testing to all isolates.
Our findings highlight that triazole resistance in environmental A. fumigatus is a con-
cern in several American countries supporting the need to establish local and national con-
tinuous surveillance programs in clinical and environmental settings of triazole-resistance
in A. fumigatus in addition to rapid diagnostics capabilities and awareness amongst pro-
fessionals. It is essential to closely monitor the current and evolving triazole-resistance
situation to establish local recommendations for the initial treatment of invasive aspergillo-
sis. This study provides further evidence that triazole resistance in A. fumigatus is a global
concern that requires epidemiological surveillance studies in countries still lacking this
information.
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